NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, which is in a Phase 1b/2 study in patients with metastatic colorectal cancer. The company also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer; and initiated a Phase 1b/2 modular study of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. Its pipeline also comprises NUC-7738, a transformation of 3'-deoxyadenosine that is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Dettagli
Tipi di conto
CFD Trading: MetaTrader 5
CFD Trading: MetaTrader 5
Investing: Web
Commissione
0.1%
Sessione trading (UTC)
Aperta oraChiusa oraChiudeApre
alle
-
Gli orari di apertura sono indicati nel tuo fuso orario locale
(UTC)
Apri un conto e investi subito con Metadoro. Invita gli amici e verrai ricompensato per la loro operatività. Troverai maggiori informazioni sul programma di affiliazione nella tua area personale.
Grazie per la visita metadoro.com. Questo sito Web è gestito da RHC Investments, che è autorizzata e regolamentata come rivenditore di investimenti dalla Financial Services Commission di Mauritius con numero di licenza C115015381. Mauritius non fa parte del quadro normativo europeo e non rientra nell'ambito di applicazione (tra gli altri) della Direttiva sui mercati degli strumenti finanziari (MiFID) II.
Continuando confermi che la decisione è presa in modo indipendente e di tua esclusiva iniziativa e che nessuna sollecitazione o raccomandazione è stata fatta da RHC Investments.
Personalizza l'abbonamento a modo tuo!Create a Newsletter
Customize your subscriptions the way you want!
Analytics
Get notified upon new posts
Select category
Price alerts
Rilevamento tempestivo di alti e bassi del mercato, fluttuazioni, ecc.
Select category
Alert method
All categoriescategoriesAll instrumentsinstrumentssearchNothing found